STAT Plus: Pharmalittle: Canadians worried by Trump importation plan; pharma creates R&D hubs in China for data
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to catch up on some reading, putter around the Pharmalot grounds, and take a nap or two. And what about you? Have you booked your summer getaway yet? You can still make plans. Meanwhile, this is a lovely time of year to enjoy the great outdoors, curl up with an ebook, or make time for someone special. Those of you tracking current events — and feeling mischievous — might want to compare the type of rats in Baltimore with those in Washington. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you after our own break — we are off next week. Ta-ta. …
The Trump administration plan to let Americans legally import cheaper prescription drugs from Canada is causing concern among Canadians who fear it could cause shortages of some medications, the Associated Press reports. Moreover, officials were surprised because they say they weren’t consulted about a possible influx of U.S. drug buyers. Health Minister Ginette Petitpas Taylor’s office said in a statement that, “while we’re aware of ongoing state-led initiatives to import Canadian drugs, we weren’t consulted on specifics.”
Continue to STAT Plus to read the full story…
